Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-05-24
2011-05-24
Gabel, Gailene R (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007100, C435S287200, C436S513000, C436S517000, C436S518000, C436S523000, C436S526000, C436S538000, C436S540000, C436S010000, C436S018000, C436S172000, C436S175000, C422S073000, C422S082080, C422S082090, C424S009200
Reexamination Certificate
active
07947465
ABSTRACT:
Bodily fluid is analyzed for the presence of drugs of a selected panel of drugs in a simultaneous assay in which sample of the fluid is incubated with additional amounts of all drugs of the panel, antibodies specific to each of the drugs of the panel, and microparticles, the microparticles being divided into subsets, one subset for each drug in the panel and each subset distinguishable from the others. The incubation is performed in a liquid medium in which competitive binding occurs, the drugs in the sample competing with those added to the assay medium for binding to the antibodies. In one procedure, the added drugs are pre-coupled to the microparticles while the antibodies are not, and the incubation is followed by further incubating the microparticles with labeled ligands that have affinity for the antibodies. In an alternative procedure, the added drugs are not coupled to the microparticles but are pre-labeled, while the antibodies are pre-coupled to the microparticles, and the assay proceeds without further incubation. In both alternatives, the microparticles are ultimately recovered from the assay medium and from any unbound species, and the recovered microparticles are analyzed by flow cytometry to obtain indications of the presence of the various drugs in the sample in an inverse manner by detection of the label, each drug differentiable from the others by the distinguishing features of the microparticles.
REFERENCES:
patent: 5525524 (1996-06-01), Buechler et al.
patent: 5851776 (1998-12-01), Valkirs
patent: 6777190 (2004-08-01), Anderson et al.
patent: 7141431 (2006-11-01), Chandler et al.
patent: 7560239 (2009-07-01), Lin et al.
patent: 7608465 (2009-10-01), Watkins et al.
patent: 2004/0126904 (2004-07-01), Watkins et al.
patent: 2006/0099664 (2006-05-01), Ullman et al.
patent: 2009/0053832 (2009-02-01), Link et al.
patent: WO 01/79844 (2001-10-01), None
Link, W. et al.; “Development of a Multiplex Toxicology Panel of Immunoassay”; 2006,The International Association of Forensic Toxicologists, 44thInternational Meeting,pp. 1-2.
Pirnay, S.O. et al.; “Sensitive Gas Chromatography-Mass Spectrometry Method for Simultaneous Measurement of MDEA, MDMA and Metabolites HMA, MDA and HMMA in Human Urine”; 2006,Clinicla Chemistry,vol. 52, No. 9, pp. 1728-1734.
del Rosario Renato B.
King David L.
Link William F.
Sweet Randy V.
Bio-Rad Laboratories, Inc.
Gabel Gailene R
Heines M. Henry
Kilpatrick Townsend and Stockton LLP.
LandOfFree
Simultaneous assay for determining drugs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Simultaneous assay for determining drugs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Simultaneous assay for determining drugs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2698947